FindTrial
Sign In

I8F-MC-GPHJ: A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 mg in Adults Who Have Obesity or Overweight with Weight-Related Comorbidities

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-501106-35-00
Acronym
17203
Enrollment
143
Registered
2023-01-26
Start date
Unknown
Completion date
2023-10-10
Last updated
2023-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity Overweight

Brief summary

Percent Change from Baseline in Body Weight

Detailed description

Percentage of Participants Who Achieve ≥10% Body Weight Reduction, Percentage of Participants Who Achieve ≥15% Body Weight Reduction, Percentage of Participants Who Achieve ≥20% Body Weight Reduction, Percentage of Participants Who Achieve ≥25% Body Weight Reduction, Change from Baseline in Waist Circumference Centimeter (cm), Change from Baseline in Who Achieve ≥30% Body Weight Reduction, Change from Baseline in Body Mass Index (BMI)

Interventions

DRUGTirzepatide
DRUGSEMAGLUTIDE

Sponsors

Eli Lilly & Co.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Percent Change from Baseline in Body Weight—

Secondary

MeasureTime frame
Percentage of Participants Who Achieve ≥10% Body Weight Reduction, Percentage of Participants Who Achieve ≥15% Body Weight Reduction, Percentage of Participants Who Achieve ≥20% Body Weight Reduction, Percentage of Participants Who Achieve ≥25% Body Weight Reduction, Change from Baseline in Waist Circumference Centimeter (cm), Change from Baseline in Who Achieve ≥30% Body Weight Reduction, Change from Baseline in Body Mass Index (BMI)—

Countries

Belgium, Germany, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026